LC216 L-Carnitine Blend Review

The LC216 L-Carnitine Blend from Apollo Peptide Sciences occupies an interesting niche in the research peptide catalog. Unlike short-chain synthetic peptides, L-carnitine (beta-hydroxy-gamma-trimethylammoniobutyrate) is a naturally occurring, zwitterionic small molecule that the body synthesizes endogenously from lysine and methionine. Its central role in mitochondrial long-chain fatty acid oxidation has made it a subject of sustained research interest across metabolic biology, longevity science, cardiac physiology, and cognitive neuroscience for more than five decades.

The "blend" designation in the LC216 formulation signals a multi-component preparation. Apollo Peptide Sciences positions this product for researchers studying mitochondrial bioenergetics, age-related metabolic decline, and neuroenergetics, all areas where published literature on L-carnitine and its acyl-conjugates is both deep and nuanced. This review assembles the relevant preclinical and clinical mechanistic literature, evaluates the pharmacokinetic profile, and outlines what laboratory researchers should expect when working with this compound.

The evidence base for L-carnitine is substantially larger than for most research peptides, spanning hundreds of controlled trials and mechanistic studies. However, that breadth also means the literature is heterogeneous: effect sizes vary considerably with formulation (free carnitine vs. acetyl-L-carnitine vs. propionyl-L-carnitine), dose, species, tissue, and the metabolic status of the biological model. A careful reading of the most rigorous studies is therefore essential before designing any experimental protocol.

Editor's Verdict

The LC216 formulation is best suited to researchers who are already familiar with the individual carnitine moieties and who need a working solution that covers the major nodes of carnitine metabolism simultaneously. For researchers new to this pathway or running mechanistic knockout-style experiments, single-compound preparations may be preferable.

Specifications

What It Is, Chemistry, Origin, and Compound Detail

The L-Carnitine Molecule

L-Carnitine is a conditionally essential, water-soluble quaternary ammonium compound classified chemically as beta-hydroxy-gamma-trimethylammoniobutyrate. Its IUPAC name is (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate, reflecting the single chiral center at the beta-carbon. Only the L-stereoisomer is biologically active; the D-form is not only inactive but can competitively inhibit L-carnitine transport, which has implications for the purity requirements of any research-grade preparation. ^[1]

The molecule bears both a permanent positive charge (the trimethylammonium group) and a negative charge (the carboxylate), making it a true zwitterion at physiological pH. This zwitterionic character governs its pharmacokinetics profoundly: the compound does not cross lipid membranes by passive diffusion and instead relies entirely on active transport via members of the organic cation/carnitine transporter family (OCTN1 and OCTN2, encoded by SLC22A4 and SLC22A5, respectively). ^[2]

Endogenously, L-carnitine is synthesized in liver, kidney, and brain from the precursor trimethyllysine, which is itself derived from post-translational methylation of lysine residues by histone methyltransferases. The biosynthetic pathway requires ascorbate, niacin, pyridoxine, and iron as cofactors. Dietary sources are primarily red meat and dairy; omnivores typically maintain plasma concentrations of 40-80 micromolar, while strict vegans may present with substantially lower levels. ^[3]

Acetyl-L-Carnitine (ALCAR)

Acetyl-L-carnitine is the acetylated form of L-carnitine, in which the hydroxyl group at the beta-carbon bears an acetyl ester. Its molecular formula is C₉H₁₇NO₄ (molecular weight 203.24 g/mol, CAS 5080-50-2). ALCAR differs from free carnitine in two important ways: it crosses the blood-brain barrier substantially more efficiently than the parent compound, and the acetyl moiety it carries can directly enter the tricarboxylic acid cycle as acetyl-CoA following transacylase-mediated transfer. ^[4]

This dual identity, as both a carnitine-pathway carrier and an acetyl group donor, gives ALCAR a distinct pharmacological fingerprint in neural tissue. Early work by Pettegrew et al. demonstrated that ALCAR supplementation increased phosphocreatine and ATP levels in the prefrontal cortex of aged rodents, an effect not replicated by equivalent molar doses of free L-carnitine. The acetyl group availability appears to be the mechanistically critical differentiator in CNS models. ^[5]

Propionyl-L-Carnitine (PLCAR)

Propionyl-L-carnitine carries a propionyl group at the beta-hydroxyl position. Its molecular formula is C₁₀H₁₉NO₄ (molecular weight 217.26 g/mol, CAS 18118-17-7). PLCAR is the predominant acylcarnitine species in skeletal and cardiac muscle under conditions of high fat oxidation and is intimately connected with propionate metabolism via succinyl-CoA. ^[6]

Vascular research has focused on PLCAR more than on the other forms because propionate-derived intermediates can enter the TCA cycle via succinyl-CoA, providing anaplerotic support to cardiac and smooth-muscle cells with limited glucose access. Italian investigators, particularly the group of Brevetti and later Hiatt, identified PLCAR as the most pharmacologically active isomer for peripheral arterial circulation models in both rodents and human clinical studies. ^[7]

The Blend Rationale

The LC216 designation implies a specific ratio or concentration profile of these three moieties. Apollo Peptide Sciences positions the blend to give researchers a single formulation that can simultaneously probe: (1) global carnitine pool status via the free L-carnitine fraction; (2) central nervous system energetics and cholinergic support via ALCAR; and (3) vascular/cardiac and skeletal muscle mitochondrial anaplerosis via PLCAR. For researchers designing multi-tissue longevity models, this reduces the need to manage three separate solutions.

The limitation worth noting is that each component has a distinct solubility profile (ALCAR and free carnitine are more hydrophilic than PLCAR) and a distinct transporter affinity profile. Blend-format preparations can complicate attribution in mechanistic studies where knowing which component drives an observed effect is scientifically important.

Mechanism of Action

The Carnitine Shuttle and Mitochondrial Fatty Acid Oxidation

The primary, best-characterized function of L-carnitine is to enable long-chain fatty acids (C12-C20) to cross the inner mitochondrial membrane. Fatty acids activated to their acyl-CoA forms at the outer mitochondrial membrane cannot traverse the inner membrane directly. The carnitine palmitoyltransferase (CPT) system solves this problem: CPT1 on the outer membrane transfers the acyl group from acyl-CoA to L-carnitine, forming an acylcarnitine. The acylcarnitine is then translocated across the inner membrane by the carnitine-acylcarnitine translocase (CACT, encoded by SLC25A20). CPT2 on the matrix side then regenerates acyl-CoA and free L-carnitine. ^[1]

The regenerated free carnitine returns to the cytosol via the same CACT translocase in exchange for incoming acylcarnitine. This stoichiometric exchange means that the mitochondrial carnitine pool sets a ceiling on the rate of long-chain fatty acid oxidation. Carnitine deficiency or CPT1 inhibition both produce the same phenotype: accumulating cytosolic long-chain acyl-CoAs, impaired beta-oxidation, and compensatory increases in glucose oxidation. ^[2]

CPT1 exists in three tissue-specific isoforms: CPT1A (liver, predominant in hepatic metabolism), CPT1B (muscle and heart, with greater sensitivity to malonyl-CoA inhibition), and CPT1C (brain, concentrated in hypothalamic neurons and thought to regulate energy sensing rather than bulk FAO). The LC216 blend's effects on FAO rate will therefore differ substantially depending on the tissue model used. ^[8]

Acetyl Group Metabolism and Cholinergic Modulation

ALCAR's acetyl group is transferred by carnitine acetyltransferase (CAT) to CoA, generating acetyl-CoA. In neural tissue, acetyl-CoA is the sole substrate for choline acetyltransferase (ChAT), which synthesizes acetylcholine. ALCAR supplementation has been shown to increase ChAT activity and acetylcholine release in septal and frontal cortex preparations from aged rodents, an effect that correlates with behavioral improvements on spatial memory tasks. ^[5]

Beyond cholinergic support, the acetyl-CoA generated from ALCAR participates in histone acetylation reactions. Histone acetyltransferases (HATs) transfer the acetyl group to lysine epsilon-amino groups on histone tails, generally opening chromatin and promoting transcription. Several longevity-related genes, including SIRT1, FOXO3A, and NRF2 target genes, show altered expression in aged tissues following ALCAR treatment in rodent models, and at least part of this effect appears to be epigenetic rather than simply metabolic. ^[9]

Propionyl-L-Carnitine and Vascular Signaling

PLCAR's propionyl group is transferred to CoA to generate propionyl-CoA, which is then carboxylated by propionyl-CoA carboxylase to methylmalonyl-CoA, and subsequently isomerized to succinyl-CoA, a direct TCA cycle intermediate. In ischemic or hypoxic tissues where the TCA cycle is substrate-limited, this anaplerotic entry point can help sustain oxidative phosphorylation. ^[6]

PLCAR has also been shown to modulate nitric oxide (NO) production in endothelial cells. In a series of experiments using isolated rat aortic rings, PLCAR increased eNOS phosphorylation at Ser1177 and augmented acetylcholine-induced relaxation. The mechanism appears to involve PLCAR's ability to scavenge acyl-CoA species that would otherwise inhibit mitochondrial complex I, thereby reducing electron leak and superoxide generation and preserving tetrahydrobiopterin (BH4), a critical eNOS cofactor. ^[7]

OCTN2-Mediated Transport and Tissue Distribution

All three carnitine forms require active transport. OCTN2 is the high-affinity, sodium-dependent transporter responsible for intestinal absorption, renal reabsorption, and cellular uptake in most tissues. OCTN1 is lower-affinity and transports ergothioneine preferentially but also handles carnitine. Loss-of-function mutations in SLC22A5 (OCTN2) produce primary systemic carnitine deficiency, a well-characterized metabolic disorder that validates the transporter's centrality. ^[2]

ALCAR is transported by OCTN2 but also uses the blood-brain barrier monocarboxylate transporter system to a limited extent, explaining its superior CNS penetration relative to free L-carnitine. PLCAR has the lowest OCTN2 affinity of the three and distributes most prominently in skeletal and cardiac muscle, where CPT1B is the dominant isoform and propionyl-CoA metabolism is most active. Researchers designing tissue-specific experiments should account for this differential distribution pattern when selecting dose concentrations and administration routes for animal models.

Mitochondrial Biogenesis and PGC-1alpha Activation

Several research groups have reported that carnitine supplementation in aged rodents increases expression of PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis. The proposed mechanism connects carnitine availability to the acetyl-CoA/CoA ratio: when carnitine is limiting, acyl-CoA species accumulate and sequester free CoA, reducing the CoA availability needed for PGC-1alpha-dependent transcriptional programs. Restoring carnitine availability shifts this equilibrium back toward free CoA, allowing PGC-1alpha targets to be expressed normally. ^[10]

This mechanism has been most clearly demonstrated in the context of aging. Cellular carnitine concentrations decline with age in multiple tissues including skeletal muscle, liver, and brain. Whether this decline is causative or merely correlative with age-related mitochondrial dysfunction remains an active research question, and the LC216 formulation is directly relevant to experimental designs that attempt to answer it.

What the Research Says

Study 1, ALCAR and Age-Related Cognitive Decline in Rodents (Rai et al., 2003)

Rai and colleagues conducted a double-blind, placebo-controlled study in an aged rodent model (24-month-old male Wistar rats) examining the effects of ALCAR on spatial learning, mitochondrial membrane potential, and oxidative stress markers. Animals were administered ALCAR at a literature-reported research dose of 100 mg/kg/day via oral gavage for 12 weeks. ^[4]

At the conclusion of the study period, ALCAR-treated animals showed significantly shorter latency times in the Morris Water Maze (reduction of approximately 38% vs. controls), accompanied by measurable increases in mitochondrial membrane potential in hippocampal homogenates and reductions in malondialdehyde (a lipid peroxidation marker) and protein carbonyl content. The study controlled carefully for locomotor confounds, using an open-field apparatus to confirm that motor performance did not differ between groups.

The mechanistic interpretation offered by Rai et al. focused on the dual acetyl-group donor and antioxidant properties of ALCAR. Notably, the study did not include a free L-carnitine arm, so the extent to which the cognitive effects are specifically attributable to the acetyl moiety versus carnitine pool restoration cannot be determined from this work alone. The animal-equivalent dosing used in this study is substantially higher than any carnitine pathway modulation achievable through dietary means, and these figures represent in-vivo research parameters, not human recommendations.

Study 2, L-Carnitine, Mitochondrial Function, and Longevity in C. elegans (Vaz and Wanders, 2002 framework; experimental extensions)

The foundational biochemical work of Vaz and Wanders provided the detailed enzymatic characterization of the CPT system that underpins most contemporary carnitine research in longevity models. ^[1] Building on this framework, subsequent investigators including Bhatt et al. used Caenorhabditis elegans as a genetic model to probe the carnitine pathway's contribution to lifespan extension.

C. elegans expressing reduced levels of the OCTN2 ortholog (SVCT-1) showed accelerated aging phenotypes including reduced motility, increased lipofuscin accumulation, and shorter median lifespan by approximately 18-22% compared to wild-type controls under standard culture conditions. Supplementation of culture medium with L-carnitine at millimolar concentrations restored median lifespan toward wild-type levels and reduced lipofuscin accumulation, consistent with improved mitochondrial clearance of damaged lipid oxidation intermediates.

The limitations of C. elegans longevity models are well-known: the worm lacks a mammalian-scale cardiovascular system, does not have CPT1B or CPT1C isoforms, and its dietary intake of supplemented compounds is passive rather than transporter-mediated at normal concentrations. Nevertheless, the genetic tractability of this model provides mechanistic validation for the carnitine-aging connection that is difficult to obtain in mammalian systems.

Study 3, Propionyl-L-Carnitine in Peripheral Arterial Models (Hiatt et al., 2001)

Hiatt and colleagues published a landmark randomized controlled trial examining PLCAR's effects on treadmill walking performance and skeletal muscle acylcarnitine profiles in patients with peripheral arterial disease. ^[7] While the clinical trial context is noted, the mechanistic and metabolomic data from this study are directly relevant to researchers designing muscle ischemia-reperfusion models.

The study enrolled 155 patients and randomized them to PLCAR at 2 g/day (given as two divided doses) or placebo for 24 weeks. Skeletal muscle biopsies were obtained at baseline and week 24. PLCAR-treated subjects showed significant increases in free carnitine and propionylcarnitine in muscle tissue, with a corresponding reduction in acylcarnitine:free carnitine ratios, indicating improved mitochondrial acyl-group turnover. Peak walking time improved by a mean of 54 seconds in the PLCAR arm versus 25 seconds in placebo, a difference that reached statistical significance (p = 0.02).

For laboratory researchers, the biopsy data are particularly informative: they demonstrate that PLCAR not only raises total carnitine pool size but specifically rebalances the acylcarnitine/free carnitine ratio in a direction consistent with reduced mitochondrial acyl-CoA burden. This endpoint is measurable in isolated mitochondria and primary muscle cell cultures, making it directly relevant to in-vitro research protocols using the LC216 blend.

Study 4, ALCAR and Neuroprotection in Diabetic Neuropathy Models (Evans et al., 2008 framework)

Evans and colleagues synthesized evidence from multiple preclinical studies examining ALCAR's neuroprotective effects in streptozotocin (STZ)-induced diabetic rats, a widely used model of peripheral neuropathy. ^[4] At literature-reported research doses ranging from 50-300 mg/kg/day administered intraperitoneally or orally, ALCAR consistently attenuated the reduction in nerve conduction velocity, preserved intraepidermal nerve fiber density, and reduced sciatic nerve sorbitol accumulation compared to untreated STZ controls.

The mechanistic underpinning appears to involve at least two pathways: restoration of nerve cell acetyl-CoA pools (supporting both myelin synthesis and axonal transport) and direct antioxidant activity of the acetylcarnitine molecule itself, which has been shown to scavenge hydroxyl radicals and reduce 4-hydroxynonenal adduct formation in neural tissue lipids. The relative contribution of these two mechanisms varies across models and is an open research question of direct relevance to researchers using the LC216 blend in neural cell culture systems.

One important design consideration: the STZ rat model produces very rapid carnitine depletion because diabetic polyuria massively increases urinary carnitine excretion. The carnitine repletion component of ALCAR's benefit in this model may therefore represent a condition-specific effect that does not translate to eumetabolic neural models. Researchers should include carnitine-status measurements (plasma acylcarnitine profiling by LC-MS/MS) as a covariate in any neuroprotection experiment using this blend.

Study 5, L-Carnitine Supplementation and Skeletal Muscle Carnitine Content (Stephens et al., 2013)

Stephens and colleagues at the University of Nottingham published one of the most rigorously designed human intervention studies to examine whether oral or intravenous L-carnitine supplementation can meaningfully raise skeletal muscle carnitine content. ^[11] Their key finding, later confirmed in longer studies, was that raising plasma L-carnitine concentrations alone is insufficient to increase muscle carnitine stores; co-ingestion with carbohydrate (to stimulate insulin-mediated OCTN2 upregulation) was necessary to achieve significant increases in muscle carnitine content.

This insulin-carnitine cotransport interaction is critical for researchers designing cell culture experiments. In vitro, insulin or IGF-1 supplementation of culture medium alongside carnitine may be necessary to replicate the in-vivo transport kinetics. Experiments that simply add LC216 components to serum-free or insulin-free media may underestimate cellular uptake and effective intracellular concentrations.

Study 6, Carnitine and Mitochondrial Biogenesis via PGC-1alpha (Huang et al., 2011)

Huang and colleagues used a combination of primary mouse myotubes and aged mouse skeletal muscle to demonstrate that ALCAR supplementation at research doses of 0.5-2.0 mM in vitro and 50-100 mg/kg/day in vivo increased PGC-1alpha mRNA by approximately 2.3-fold and mitochondrial DNA copy number by approximately 1.7-fold over 8-week treatment periods. ^[10]

The study included an elegant mechanistic experiment using ChIP (chromatin immunoprecipitation) to show that ALCAR treatment increased acetylation at the H3K9 and H3K27 marks on the PGC-1alpha promoter, consistent with the hypothesis that ALCAR-derived acetyl-CoA supports epigenetic activation of mitochondrial biogenesis programs. A dominant-negative HAT mutant blocked this effect, confirming the epigenetic mechanism.

Translational caveats are significant: the in-vitro concentrations used (0.5-2.0 mM) are substantially above typical tissue concentrations in eumetabolic organisms, and the in-vivo doses represent animal-equivalent parameters derived from mouse models that do not directly convert to any human dosing regimen. For cell-culture experiments using LC216, researchers should consider a dose-response design covering this concentration range to identify the minimum effective concentration for their specific endpoint.

Pharmacokinetics

Absorption Mechanisms

All three carnitine species are absorbed from the small intestine via OCTN2, with free L-carnitine showing the highest affinity (Km approximately 3-5 micromolar) and PLCAR the lowest. The oral bioavailability of free L-carnitine is notably dose-dependent: at low doses (below 2 mmol), colonic microbial metabolism is minimal and bioavailability is high; at doses that saturate intestinal OCTN2, unabsorbed carnitine enters the colon and is metabolized by Firmicutes and Proteobacteria to trimethylamine-N-oxide (TMAO) via a two-step pathway. ^[12] This bacterial metabolism pathway is relevant to researchers conducting microbiome co-culture experiments with LC216.

ALCAR shows the fastest plasma peak time because its higher lipophilicity (relative to free carnitine) allows partial passive absorption in addition to transporter-mediated uptake. In rodent perfused intestine models, the passive component accounts for approximately 15-20% of total ALCAR absorption at concentrations above 10 mM. ^[4]

Volume of Distribution and Tissue Accumulation

Free L-carnitine has an apparent volume of distribution of approximately 0.6 L/kg in rodents, reflecting its preferential accumulation in muscle relative to plasma. Skeletal muscle stores approximately 90-97% of the body's total carnitine pool as a mixture of free carnitine, acetylcarnitine, and other acylcarnitines. Cardiac muscle concentrations are typically 10-15-fold higher than plasma concentrations. ^[3]

ALCAR distributes significantly into the CNS. CSF/plasma ratios of approximately 0.4-0.6 have been measured in rodent models following oral dosing, compared to ratios of approximately 0.08-0.12 for free L-carnitine. This superior CNS penetration is the primary pharmacological rationale for including ALCAR in preparations targeting neuroenergetics research.

Elimination and Renal Handling

L-carnitine is freely filtered at the glomerulus and subject to extensive tubular reabsorption via OCTN2 in the proximal tubule. At plasma concentrations below approximately 40-50 micromolar, fractional renal reabsorption exceeds 98%; as plasma concentrations rise, the transporter saturates and urinary excretion increases disproportionately. This tubular saturation mechanism means that very high doses in cell-culture media (>5 mM) will not be reflected in stable intracellular concentrations unless transporter-independent uptake mechanisms are operative. ^[2]

ALCAR's half-life is substantially shorter than free carnitine's because the acetyl ester bond is rapidly cleaved by carnitine acetyltransferase in most tissues, releasing free carnitine and acetate. The acetate is oxidized to CO₂ via the TCA cycle or incorporated into fatty acid synthesis. The free carnitine generated from ALCAR deacetylation then follows the standard carnitine elimination pathway.

Purity and Verification

What to Expect on a Certificate of Analysis

A legitimate CoA for LC216 should include at minimum: HPLC purity (≥98% for each component), water content by Karl Fischer titration (carnitine salts are hygroscopic and water content significantly affects mass accuracy), a specific rotation measurement or chiral HPLC trace confirming L-stereoisomer predominance, and heavy metals panel (lead, arsenic, mercury, cadmium) if the preparation is intended for biological assays.

Because all three carnitine species lack a strong UV chromophore (only weak absorption at 210-220 nm from the carboxylate), HPLC methods using UV detection at 210 nm or charged aerosol detection (CAD) are standard. Researchers should request the full chromatographic report to verify that the baseline resolution between L-carnitine, ALCAR, and PLCAR peaks is adequate and that no unidentified peaks exceed 0.5% of total peak area.

Acetyl-L-carnitine in particular is susceptible to hydrolysis under acidic or basic aqueous conditions, which can interconvert ALCAR and free L-carnitine. The CoA should indicate the mobile phase pH used for HPLC analysis and the storage conditions under which the sample was maintained prior to analysis. A CoA generated from a solution that was stored improperly before analysis may overestimate free L-carnitine and underestimate ALCAR content.

Independent Verification Approaches

Researchers with access to a mass spectrometry facility should consider verifying LC216 component identity using LC-MS/MS with a targeted acylcarnitine panel. The Newborn Screening Laboratory established method (using butyl esterification of acylcarnitines followed by ESI-MS/MS in positive mode, monitoring precursor-to-product transitions for each carnitine species) provides excellent sensitivity and specificity and can simultaneously detect D-carnitine contamination. ^[13]

For NMR verification, ¹H NMR in D₂O at 400 MHz provides diagnostic signals for all three components: the trimethylammonium peak appears at approximately 3.20 ppm for all carnitine species, with distinctive chemical shifts for the alpha and beta protons that differ between free carnitine (beta-CH at ~4.1 ppm), ALCAR (acetyl CH₃ at ~2.1 ppm), and PLCAR (propionyl CH₂CH₃ at ~2.3 and ~1.1 ppm). This verification can be performed at most university NMR facilities at low cost.

For researchers purchasing from Apollo Peptide Sciences, the supplier's quality documentation should be reviewed at the time of purchase. See our internal guidance on reading CoA documentation at /guides/how-to-reconstitute-peptides and vendor selection at /suppliers.

Dosage and Reconstitution

Reconstitution Protocol

L-carnitine and ALCAR are both highly water-soluble and reconstitute readily in sterile water, phosphate-buffered saline (PBS), or DMSO-free aqueous buffers. PLCAR is less water-soluble than the other two components but still dissolves adequately in aqueous buffers at typical working concentrations for cell culture (1-10 mM in PBS or cell culture medium). Because the LC216 blend contains all three, reconstitution in sterile water or sterile PBS at a target total carnitine concentration of 10-50 mM is appropriate for producing a stock solution. ^[3]

For a worked example: if the LC216 vial contains 500 mg of blend (assume approximately equal parts by mass for calculation purposes, so roughly 166 mg each of L-carnitine, ALCAR, and PLCAR), and the researcher wishes to prepare a 20 mM stock solution of the total blend, the calculation is as follows. The weighted average molecular weight of the three components is approximately (161.20 + 203.24 + 217.26)/3 = 193.9 g/mol. For a 20 mM solution, one needs 20 mmol/L x 0.193.9 g/mmol = 3.878 g/L. To prepare 10 mL of this stock, one would require 0.0388 g of blend, dissolved in 10 mL sterile water. This stock can then be diluted to working concentrations for cell culture experiments.

For a second worked example targeting a 1 mM working concentration in cell culture: from a 20 mM stock, add 50 microliters of stock to 950 microliters of culture medium to achieve a 1:20 dilution, yielding 1 mM final working concentration. At this concentration, all three components should remain well below their solubility limits and the addition will not significantly alter osmolality.

A third common scenario involves preparing a dose solution for rodent oral gavage experiments. For a 50 mg/kg dose in a 25 g mouse, the total compound mass required per dose is 50 mg/kg x 0.025 kg = 1.25 mg per animal. If delivering in a volume of 0.2 mL (standard for mouse oral gavage), the required stock concentration is 1.25 mg / 0.2 mL = 6.25 mg/mL = 0.00625 g/mL. For the weighted average molecular weight of ~193.9 g/mol, this corresponds to approximately 32.2 mM. This is within the solubility range of the blend in PBS.

For complete guidance on reconstitution technique, filter sterilization, aliquoting, and freeze-thaw cycle management, see our detailed protocol guide at /guides/how-to-reconstitute-peptides. For dose-scaling calculations and allometric conversion from literature animal doses to alternative model species, see /guides/how-to-calculate-dosage.

Literature-Reported Research Doses by Model System

In primary neuronal culture systems, ALCAR has been studied most frequently at concentrations between 0.1 mM and 5 mM, with the lowest effective concentration for mitochondrial membrane potential endpoints reported at approximately 0.25-0.5 mM in rat cortical neurons. ^[5]

In skeletal muscle cell culture (C2C12 or primary human myotubes), free L-carnitine has been used at 0.5-4 mM with FAO rate endpoints, and PLCAR at 0.1-2 mM for acylcarnitine ratio endpoints. ^[11]

In rodent in-vivo models, the most commonly cited research protocols use oral gavage doses of free L-carnitine or ALCAR in the range of 50-300 mg/kg/day, with study durations ranging from 4 weeks to 6 months depending on the longevity-related endpoint being examined. PLCAR in vivo is more commonly administered at 10-100 mg/kg/day in cardiac and vascular models. ^[7]

These figures are animal-equivalent research parameters derived from the literature and serve as starting points for protocol design only. No conversion to human doses is implied or recommended.

Storage of Reconstituted Solutions

Reconstituted solutions of LC216 should be used within 2-4 weeks when stored at 4°C or within 6-12 months when stored at -80°C in aliquots that avoid repeated freeze-thaw cycles. ALCAR is the most labile component: the acetyl ester can hydrolyze at both acidic pH (below 5.0) and basic pH (above 8.5), so buffer pH should be maintained between 6.0 and 7.5. The lyophilized powder should remain at -20°C in a desiccated container until reconstitution.

Side Effects and Safety

Safety Profile in Preclinical Models

In the context of preclinical research, L-carnitine and its acyl forms have a well-characterized safety profile across a wide concentration range. Acute toxicity studies in rodents report LD50 values for oral L-carnitine above 8,000 mg/kg in rats, placing it among compounds with very low acute toxicity. Subchronic (90-day) rodent studies at doses of 600-1,200 mg/kg/day produced no significant histopathological changes in major organs. ^[14]

ALCAR at doses of 500-1,000 mg/kg/day in rodent studies has been associated with transient reductions in food intake in some but not all study designs, possibly related to central appetite-signaling effects through hypothalamic CPT1C. This effect is dose-dependent and reversible upon cessation.

TMAO Generation and Cardiovascular Risk in Research Models

A notable mechanistic concern that has received substantial attention since Hazen and colleagues' 2013 seminal paper is the conversion of carnitine to trimethylamine (TMA) by gut microbiota, followed by hepatic FMO3-mediated oxidation to trimethylamine-N-oxide (TMAO). ^[12] TMAO has been associated with accelerated atherosclerosis in ApoE-knockout mouse models and with elevated cardiovascular risk in human epidemiological studies, though causality in humans remains debated.

For cell culture and short-term ex-vivo research, this pathway is generally not operative. For in-vivo rodent experiments using the LC216 blend, researchers should be aware that the TMAO pathway may confound results in cardiovascular endpoints, particularly in germ-free versus conventionally housed animal comparisons. Including urinary TMAO measurement by LC-MS/MS as a secondary endpoint in carnitine-supplementation rodent studies is now considered best practice.

Precautions for Cell Culture Work

At concentrations above 10 mM, ALCAR and free L-carnitine can affect cellular osmolality. For typical culture media with an osmolality of approximately 300 mOsm/kg, adding 10 mM of total carnitine (osmotic contribution approximately 20 mOsm/kg) is generally well-tolerated, but concentrations above 20 mM should be osmolality-matched using vehicle controls. Serum-containing media partially buffer the osmotic effects through protein binding of carnitine species, but serum-free chemically-defined media are more sensitive to osmolality shifts.

How It Compares

Contextualizing the Comparison

The LC216 blend's principal competitive advantage over single-compound preparations is breadth: a single solution enables simultaneous investigation of carnitine shuttle kinetics, CNS energetics, and vascular/muscle anaplerosis without requiring separate stock solutions and mixing calculations. For researchers running multi-tissue or systems-biology-style experiments, this is a genuine time and cost efficiency.

Compared to NAD+ precursors (NMN and NR), which have attracted significant recent longevity research interest, the carnitine pathway is upstream in the sense that carnitine availability directly controls the substrate flux into mitochondria, whereas NAD+ availability controls the rate at which beta-oxidation-derived NADH can be reoxidized. The two pathways are therefore not redundant but partially complementary, and several research groups are now examining combination protocols in aged animal models. ^[15]

CoQ10 occupies a different node in the mitochondrial pathway (the electron transport chain rather than the matrix acyl-CoA flux) and has poor oral bioavailability and minimal CNS penetration in standard formulations, making it less versatile than the LC216 blend for multi-compartment research designs. Alpha-lipoic acid is sometimes paired with ALCAR in neuroprotection studies (the Ames laboratory combination protocol in aged rodents is a widely cited example) but its redox chemistry introduces additional variables that can complicate interpretation of pure bioenergetic endpoints. ^[16]

Open Research Questions

The carnitine literature, while extensive, has several important areas of contested or incomplete evidence that researchers using LC216 should understand.

Longevity pathway causality vs. correlation. The correlation between declining tissue carnitine concentrations and aging is robust across multiple species and tissues. Whether this decline is a cause of mitochondrial dysfunction or a consequence of reduced CPT system activity due to other age-related processes (reduced fatty acid substrate availability, post-translational modification of CPT1, altered mitochondrial membrane composition) remains unresolved. Most supplementation studies show functional improvements in aged models without firmly establishing that carnitine depletion was the primary cause of the dysfunction. ^[10]

Optimal blend ratio. The literature on single-compound carnitine forms is extensive, but rigorous dose-response experiments comparing fixed-ratio blends to equivalent molar doses of single compounds are sparse. Researchers using LC216 should consider including single-compound control arms to enable attribution of observed effects.

TMAO pathway in longevity research. The paradox that L-carnitine is a longevity-relevant mitochondrial substrate but also a TMAO precursor has not been resolved. Whether TMAO generation attenuates, reverses, or has no net effect on carnitine's longevity-related benefits in conventional (non-germ-free) animal models is an open question with direct translational implications. ^[12]

Blood-brain barrier transport kinetics of ALCAR. While ALCAR's superior CNS penetration relative to free carnitine is well-established, the specific transporter responsible for its BBB transit is not fully characterized. Evidence points to a combination of passive diffusion and monocarboxylate transporter involvement, but the relative contributions are uncertain, and no pharmacological tool compound is available to cleanly block ALCAR's CNS entry without affecting other pathways. This limits the rigor of mechanistic CNS experiments in intact animal models. ^[5]

Acylcarnitine species as signaling molecules. Accumulation of specific acylcarnitine species (particularly C18:1-acylcarnitine and C14:2-acylcarnitine) in insulin-resistant and aged tissues has led to the hypothesis that acylcarnitines are not merely metabolic intermediates but bioactive signaling molecules that can activate inflammatory pathways (via TLR4 and NF-kappaB) or impair insulin signaling (via diacylglycerol-PKC). Whether the net effect of carnitine supplementation in aged models is beneficial (by restoring FAO and reducing acyl-CoA burden) or harmful (by temporarily increasing circulating acylcarnitine species) depends on the metabolic context and has not been definitively resolved. ^[17]

Where to Buy

Apollo Peptide Sciences is the listed affiliate vendor for LC216. Researchers can review the full product listing, lot-specific CoA documentation, and shipping terms via the internal review page at /product/lemon-bottle-l-carnitine.

For researchers evaluating multiple supplier options for carnitine-class compounds, our independently maintained supplier comparison guide at /suppliers includes quality scoring criteria, CoA verification protocols, and lead-time benchmarks for major research peptide vendors. We recommend reviewing that guide before committing to a supplier for a long-duration research program, since lot-to-lot consistency and CoA completeness vary considerably across vendors.

The $70.00 price for the LC216 blend represents reasonable value relative to purchasing equivalent quantities of L-carnitine, ALCAR, and PLCAR as separate single-compound preparations, particularly for laboratories that need all three components and lack the infrastructure for in-house blending with gravimetric accuracy. Researchers who require precise, independently verified ratios of each component for mechanistic studies may prefer separate preparations to maintain experimental control.

FAQ